You are here

Gilead saves US$10b in taxes as pricey hep C drug takes off

This boosts its already huge profits, letting firm stash even more billions in tax havens abroad, says advocacy group
Friday, July 15, 2016 - 05:50
BT_20160715_NAHGILEAD15_2386962.jpg
A drug-preparing process at a Gilead lab. The firm prices its full, 12-week Sovaldi-based hep C treatment course at US$94,500.

New York

GILEAD Sciences Inc's profit margin has soared and its tax rate has plummeted since the drugmaker introduced its controversial US$1,000-a- day medication for hepatitis C, according to a report by an advocacy group that accuses the company of using accounting gimmicks to stash